Readoutin 14d
AskGene Pharma, Inc. — ASKB589
Phase 3 primary completion: ASKB589 with CAPOX and PD-1 inhibitor in advanced or metastatic GC/GEJ adenocarcinoma.
- Date
- Dec 2026
- Type
- Readout
- Indication
- GC/GEJ Adenocarcinoma
Readoutin 14d
Phase 3 primary completion: ASKB589 with CAPOX and PD-1 inhibitor in advanced or metastatic GC/GEJ adenocarcinoma.
The weekly brief is free. Pro adds reminders 7 days and 1 day before.